Top ▲

phosphodiesterase 3A

Click here for help

Not curated in GtoImmuPdb

Target id: 1298

Nomenclature: phosphodiesterase 3A

Abbreviated Name: PDE3A

Family: Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs)

Annotation status:  image of a red circle Awaiting annotation  » Email us

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 6 1141 12p12.2 PDE3A phosphodiesterase 3A
Mouse 6 1141 6 G2 Pde3a phosphodiesterase 3A, cGMP inhibited
Rat 6 1141 4q44 Pde3a phosphodiesterase 3A
Previous and Unofficial Names Click here for help
CGI-PDE A | phosphodiesterase 3A cGMP inhibited | phosphodiesterase 3A, cGMP-inhibited | phosphodiesterase 3A, cGMP inhibited
Database Links Click here for help
Alphafold
BRENDA
CATH/Gene3D
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Enzyme
KEGG Gene
OMIM
Pharos
UniProtKB
Wikipedia
Enzyme Reaction Click here for help
EC Number: 3.1.4.17

Download all structure-activity data for this target as a CSV file go icon to follow link

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
compound I [WO2021143841] Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 10.5 pIC50 10
⤷ pIC50 10.5 (IC50 3x10-11 M) [10]
ensifentrine Small molecule or natural product Approved drug Click here for species-specific activity table Immunopharmacology Ligand Hs Inhibition 9.4 pIC50 2
⤷ pIC50 9.4 (IC50 4x10-10 M) [2]
Description: Inhibition of PDE3 from human platelets
anagrelide Small molecule or natural product Approved drug Primary target of this compound Ligand has a PDB structure Hs Inhibition 7.1 – 7.3 pIC50 4-6
⤷ pIC50 7.1 – 7.3 (IC50 8.2x10-8 – 5.4x10-8 M) [4-6]
cilostazol Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition 6.7 pIC50 8
⤷ pIC50 6.7 (IC50 2x10-7 M) [8]
milrinone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 6.3 – 6.4 pIC50 3,8
⤷ pIC50 6.3 – 6.4 (IC50 4.5x10-7 – 4.4x10-7 M) [3,8]
papaverine Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 6.0 pIC50 11
⤷ pIC50 6.0 (IC50 9.17x10-7 M) [11]
enoximone Small molecule or natural product Approved drug Primary target of this compound Hs Inhibition 5.4 pIC50 9
⤷ pIC50 5.4 (IC50 3.8x10-6 M) [9]
Description: Measuring inhibition of human platelet PDE
inamrinone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 4.8 pIC50 7
⤷ pIC50 4.8 (IC50 1.6x10-5 M) [7]
Description: Inhibition of PDE3 purified from human platelets, and therefore assumed to be the PDE3A subtype.
ibudilast Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 3.5 pIC50 1
⤷ pIC50 3.5 (IC50 2.99x10-4 M) [1]
Inhibitor Comments
Anagrelide is an approved drug inhibitor of PDE3A in platelets.
Amrinone (inamrinone) and cilostazol are significantly selective for the PDE3 isozymes over the other PDEs tested [8].

References

Show »

1. Allcock RW, Blakli H, Jiang Z, Johnston KA, Morgan KM, Rosair GM, Iwase K, Kohno Y, Adams DR. (2011) Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast. Bioorg Med Chem Lett, 21 (11): 3307-12. [PMID:21530250]

2. Boswell-Smith V, Spina D, Oxford AW, Comer MB, Seeds EA, Page CP. (2006) The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]. J Pharmacol Exp Ther, 318 (2): 840-8. [PMID:16682455]

3. Edmondson SD, Mastracchio A, He J, Chung CC, Forrest MJ, Hofsess S, MacIntyre E, Metzger J, O'Connor N, Patel K et al.. (2003) Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors. Bioorg Med Chem Lett, 13 (22): 3983-7. [PMID:14592490]

4. Jones GH, Venuti MC, Alvarez R, Bruno JJ, Berks AH, Prince A. (1987) Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide. J Med Chem, 30 (2): 295-303. [PMID:3027338]

5. Martinez GR, Walker KA, Hirschfeld DR, Bruno JJ, Yang DS, Maloney PJ. (1992) 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem, 35 (4): 620-8. [PMID:1311763]

6. Meanwell NA, Pearce BC, Roth HR, Smith EC, Wedding DL, Wright JJ, Buchanan JO, Baryla UM, Gamberdella M, Gillespie E et al.. (1992) Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains. J Med Chem, 35 (14): 2672-87. [PMID:1321910]

7. Sircar I, Steffen RP, Bobowski G, Burke SE, Newton RS, Weishaar RE, Bristol JA, Evans DB. (1989) Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure. J Med Chem, 32 (2): 342-50. [PMID:2536438]

8. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y, Hidaka H. (2000) Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol, 59 (4): 347-56. [PMID:10644042]

9. Venuti MC, Jones GH, Alvarez R, Bruno JJ. (1987) Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856). J Med Chem, 30 (2): 303-18. [PMID:3027339]

10. Yang M, Sun Y, Li W, Xu Z, Bao P, Gao J, Dong P, Hui H, Ji X, Luo Y. (2021) Pharmaceutical composition of tricyclic pde3/pde4 dual inhibitor compound. Patent number: WO2021143841A1. Assignee: Chia Tai Tianqing Pharmaceutical Group Co Ltd. Priority date: 15/01/2021. Publication date: 22/07/2021.

11. Zhang Z, Lu X, Xu J, Rothfuss J, Mach RH, Tu Z. (2011) Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A. Eur J Med Chem, 46 (9): 3986-95. [PMID:21705115]

Contributors

Show »

Citation information

Chen Yan.

Last modified on 09/07/2026.

The citation format for the published version of this page will be: